Science AI Journal
Medicine · Research topic

Open research questions in Pharmacology and Obesity Treatment

198 gap statements mined from Pharmacology and Obesity Treatment papers in our 7.9M-paper local library, which holds 1,236 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Pharmacology and Obesity Treatment? See the ranked Medicine journals.

What the literature leaves open

  • A limitation of this study is the small sample size and relatively short follow-up period. Therefore, larger-scale randomized studies are needed to confirm these preliminary findings.

    Inappropriate Sinus Tachycardia in Athletes: Could Nutraceuticals Play a Role? · 2025 · DOI

  • The need for increased educational efforts by physicians and pharmacists to reduce the risk of pseudoephedrine poisoning. The lack of awareness about the risks associated with pseudoephedrine use, particularly in combination with other substances.

    Pseudoephedrine intoxication: sex-specific differences in clinical symptoms · 2026 · DOI

  • Further studies are needed to confirm the long-term effects of GLP-1RAs in patients with antipsychotic-related overweight and metabolic dysregulation. Studies with larger sample sizes and longer durations are needed to provide more precise estimates of the effects of GLP-1RAs. Research is needed to investigate the effects of different GLP-1RAs on various outcomes.

    Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis · 2026 · DOI

  • The clinical features and treatment outcomes of ROHHAD syndrome in Chinese children are not well understood. The efficacy of rituximab therapy in treating the syndrome is unclear. The natural history and heterogeneity of the disease are not well understood.

    Clinical features of ROHHAD syndrome and treatment outcomes following rituximab therapy: a descriptive case series of Chinese children · 2026 · DOI

  • Future research should investigate strategies to assess for disordered eating in this population.

    Weight Loss Medications in Youth: Decision-Making Experiences, Eating Behaviors, and Uncertainty About Endpoint · 2026 · DOI

  • Semaglutide is effective for weight management, yet its integrated real-world effects on body composition, resting energy expenditure (REE), adaptive thermogenesis (AT), and muscle strength in adults with obesity without diabetes remain incompletely characterized.

    Longitudinal Changes in Body Composition, Adaptive Thermogenesis, and Muscle Strength in Patients with Obesity Treated with Semaglutide · 2026 · DOI

  • Real-world evidence of subsidised semaglutide in children with obesity is scarce.

    Real‐World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study · 2026 · DOI

  • Universal subsidisation policy enabled high treatment persistence and may inform reimbursement policy in other countries, though generalisability to settings without universal coverage remains uncertain.

    Real‐World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study · 2026 · DOI

  • Hesitancy due to safety concerns and the role of weight stigma should be explored to determine the potential impact on users of such medications when medically indicated.

    Youth Perspectives on the Use of Medications for Weight Loss · 2025 · DOI

  • There are limited studies on GLP-1 RA use for obesity in paediatric populations.

    The role of GLP ‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system · 2025 · DOI

  • There are no head-to-head trials comparing weight loss with bariatric surgery, and limited evidence for the optimal duration of treatment in non-diabetic patients.

    The role of GLP ‐1 receptor agonists in the management of obesity: risks and opportunities for the Australian health care system · 2025 · DOI

  • The purpose of this review is to describe the existing limited data related to the use of semaglutide in adolescents with obesity, supplementing with findings from adult studies of semaglutide use.

    Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice · 2024 · DOI

  • However, its long-term safety and efficacy for youth with obesity remain to be demonstrated.

    Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice · 2024 · DOI

  • GLP-1RAs may offer a promising adjunct therapy for pediatric obesity, particularly in cases where lifestyle interventions alone are insufficient.

    Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity · 2024 · DOI

  • It highlights the necessity of this investigation due to the limited knowledge on both the short-term and long-term implications of GLP-1RA on energy expenditure (EE) and energy intake (EI).

    Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists · 2024 · DOI

  • Future research should focus on systematically measuring all components of energy balance to fully elucidate the mechanisms of GLP-1RA and optimize their therapeutic use for personalized medicine.

    Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists · 2024 · DOI

  • Recent guidelines support use of anti-obesity pharmacotherapy for adolescents with obesity, but the potential impact on disparities in obesity prevalence has not been evaluated.

    Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity · 2024 · DOI

  • Unwillingness was associated with beliefs that patients would not continue AOM long enough for benefit and that there was insufficient time or resources to implement.

    Primary care perspectives on prescribing anti‐obesity medication for adolescents · 2024 · DOI

  • The current approach to obesity management is often inadequate, focusing solely on individual factors. There is a need for a comprehensive approach, considering lifestyle and environmental factors.

    Current diagnostic and therapeutic approaches in obesity management · 2026 · DOI

  • Future updates may incorporate evolving standards in the definition and management of obesity, broader patient populations and geographic settings, new pharmacotherapies and formulations, and additional clinically relevant endpoints as the evidence base develops.

    Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update · 2026 · DOI

  • The evidence base for several complication domains remains sparse or heterogeneous. Several clinically important outcomes are not yet represented as distinct domains in the algorithm.

    Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update · 2026 · DOI

  • The study notes the challenges of treating obesity, including the need for effective pharmacological therapies and the limitations of access to these therapies. The study notes the challenges of individualizing treatment and considering comorbidities.

    Eficácia clínica e efeitos metabólicos dos agonistas de GLP-1 e GIP no tratamento da obesidade: uma revisão integrativa · 2026 · DOI

  • The study has limitations, including the potential for bias in the selected articles and the need for continuous use of the medications to maintain results. The study also notes the importance of individualizing treatment, considering comorbidities and the need for continuous treatment.

    Eficácia clínica e efeitos metabólicos dos agonistas de GLP-1 e GIP no tratamento da obesidade: uma revisão integrativa · 2026 · DOI

  • Obesity and excessive adiposity have a growing prevalence worldwide, constituting important challenges for public health. The disease hepática esteatótica associada à disfunção metabólica (MASLD) represents the most common form of chronic liver disease worldwide. There is a need to understand the impacts of tirzepatide use in the management of obesity-associated hepatic steatosis.

    Efeitos da Tirzepatida na Doença Hepática Esteatótica associada à disfunção metabólica em pacientes com obesidade: uma revisão integrativa · 2026 · DOI

  • The certainty of evidence for some outcomes was downgraded due to serious inconsistency and risk of bias. The sample size was limited for some outcomes. The duration of the trials ranged from 12 to 36 weeks, which may not be sufficient to capture long-term effects. Some trials raised concerns regarding deviations from intended interventions and missing outcome data.

    Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis · 2026 · DOI

Most-cited papers in Pharmacology and Obesity Treatment

Most recent work

Find a gap in your own Pharmacology and Obesity Treatment sub-topic

This page shows what the Pharmacology and Obesity Treatment literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) The lack of awareness about the risks associated with pseudoephedrine use, particularly in combination with other substances (“Pseudoephedrine intoxication: sex-specific differences in clinical symptoms”, 2026); (2) Further studies are needed to confirm the long-term effects of GLP-1RAs in patients with antipsychotic-related overweight and metabolic dysregulation (“Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related…”, 2026); (3) The clinical features and treatment outcomes of ROHHAD syndrome in Chinese children are not well understood (“Clinical features of ROHHAD syndrome and treatment outcomes following rituximab…”, 2026); (4) Future research should investigate strategies to assess for disordered eating in this population (“Weight Loss Medications in Youth: Decision-Making Experiences, Eating…”, 2026); (5) Real-world evidence of subsidised semaglutide in children with obesity is scarce (“Real‐World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A…”, 2026). 198 gap statements have been mined from Pharmacology and Obesity Treatment papers in our 7.9M-paper local library, which holds 1,236 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.